AAPL279.02-14.16 (-4.83%) ▼|ABBV243.26+8.37 (+3.56%) ▲|ABT93.23+2.74 (+3.03%) ▲|ACN126.41-2.74 (-2.12%) ▼|ADBE194.90-1.65 (-0.84%) ▼|AMAT650.79+61.82 (+10.50%) ▲|AMD523.82+4.77 (+0.92%) ▲|AMGN355.22+3.83 (+1.09%) ▲|AMT169.19-5.27 (-3.02%) ▼|AMZN228.83-5.54 (-2.36%) ▼|AVGO379.26-2.82 (-0.74%) ▼|AXP341.68-0.88 (-0.26%) ▼|BA218.26-1.99 (-0.90%) ▼|BAC58.19+0.46 (+0.79%) ▲|BKNG179.03-2.25 (-1.24%) ▼|BLK971.21-11.39 (-1.16%) ▼|BMY55.58+0.58 (+1.05%) ▲|BNY145.32+1.76 (+1.23%) ▲|BRK-B488.49-6.32 (-1.28%) ▼|C145.32+1.73 (+1.20%) ▲|CAT1,044.33+49.88 (+5.02%) ▲|CL91.13-0.75 (-0.82%) ▼|CMCSA22.90+0.26 (+1.15%) ▲|COF203.58+3.10 (+1.55%) ▲|COP106.66-0.26 (-0.24%) ▼|COST948.42-12.55 (-1.31%) ▼|CRM150.00-2.76 (-1.81%) ▼|CSCO118.91-0.83 (-0.69%) ▼|CVS104.47+2.60 (+2.55%) ▲|CVX172.49+1.04 (+0.60%) ▲|DE622.68+21.93 (+3.65%) ▲|DHR194.40+5.53 (+2.93%) ▲|DIS98.63-2.50 (-2.47%) ▼|DUK127.45+0.92 (+0.73%) ▲|EMR143.48+2.04 (+1.44%) ▲|FDX325.11+8.28 (+2.61%) ▲|GD344.82+0.50 (+0.15%) ▲|GE370.58+4.70 (+1.28%) ▲|GEV1,084.85+27.20 (+2.57%) ▲|GILD124.26-0.89 (-0.71%) ▼|GM78.51-0.44 (-0.56%) ▼|GOOG339.93-5.10 (-1.48%) ▼|GOOGL342.25-3.03 (-0.88%) ▼|GS1,069.25-7.66 (-0.71%) ▼|HD342.30-0.56 (-0.16%) ▼|HON230.85+3.43 (+1.51%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC130.00-1.91 (-1.45%) ▼|INTU255.66-6.67 (-2.54%) ▼|ISRG400.58-1.25 (-0.31%) ▼|JNJ245.87+4.87 (+2.02%) ▲|JPM335.97+2.52 (+0.76%) ▲|KO80.39-0.22 (-0.27%) ▼|LIN523.82+8.09 (+1.57%) ▲|LLY1,133.57+16.31 (+1.46%) ▲|LMT505.41+13.77 (+2.80%) ▲|LOW220.47-0.99 (-0.44%) ▼|LRCX393.43+18.61 (+4.97%) ▲|MA493.67-0.74 (-0.15%) ▼|MCD266.69-7.19 (-2.63%) ▼|MDLZ61.64-0.11 (-0.17%) ▼|MDT80.81+0.68 (+0.85%) ▲|META546.15-11.65 (-2.09%) ▼|MMM167.12+1.21 (+0.73%) ▲|MO73.35+1.28 (+1.77%) ▲|MRK125.59+4.99 (+4.13%) ▲|MS221.28+1.42 (+0.65%) ▲|MSFT354.78-10.67 (-2.92%) ▼|MU1,221.22+173.30 (+16.54%) ▲|NEE87.87+0.25 (+0.28%) ▲|NFLX72.05+0.20 (+0.28%) ▲|NKE40.48-1.35 (-3.22%) ▼|NOW90.27-3.53 (-3.76%) ▼|NVDA194.52-4.39 (-2.21%) ▼|ORCL152.56-4.98 (-3.16%) ▼|PEP139.88-2.39 (-1.68%) ▼|PFE23.81-0.24 (-0.98%) ▼|PG148.34-3.70 (-2.43%) ▼|PLTR107.72-5.79 (-5.10%) ▼|PM179.26+1.95 (+1.10%) ▲|QCOM207.57+10.25 (+5.19%) ▲|RTX186.15+1.09 (+0.59%) ▲|SBUX103.37-0.16 (-0.15%) ▼|SCHW89.51-1.88 (-2.06%) ▼|SO95.95+0.17 (+0.18%) ▲|SPG225.65+3.50 (+1.58%) ▲|T22.55+0.18 (+0.81%) ▲|TMO505.68+13.48 (+2.74%) ▲|TMUS182.60+1.81 (+1.00%) ▲|TSLA373.28-2.19 (-0.58%) ▼|TXN310.99+7.88 (+2.60%) ▲|UBER72.67-1.18 (-1.60%) ▼|UNH414.93+9.13 (+2.25%) ▲|UNP266.84+6.88 (+2.64%) ▲|UPS108.52+2.38 (+2.24%) ▲|USB61.03+0.92 (+1.53%) ▲|V334.59+2.36 (+0.71%) ▲|VZ46.13+0.45 (+0.97%) ▲|WFC84.89+0.59 (+0.70%) ▲|WMT116.30-2.71 (-2.28%) ▼|XOM137.52+0.62 (+0.45%) ▲|AAPL279.02-14.16 (-4.83%) ▼|ABBV243.26+8.37 (+3.56%) ▲|ABT93.23+2.74 (+3.03%) ▲|ACN126.41-2.74 (-2.12%) ▼|ADBE194.90-1.65 (-0.84%) ▼|AMAT650.79+61.82 (+10.50%) ▲|AMD523.82+4.77 (+0.92%) ▲|AMGN355.22+3.83 (+1.09%) ▲|AMT169.19-5.27 (-3.02%) ▼|AMZN228.83-5.54 (-2.36%) ▼|AVGO379.26-2.82 (-0.74%) ▼|AXP341.68-0.88 (-0.26%) ▼|BA218.26-1.99 (-0.90%) ▼|BAC58.19+0.46 (+0.79%) ▲|BKNG179.03-2.25 (-1.24%) ▼|BLK971.21-11.39 (-1.16%) ▼|BMY55.58+0.58 (+1.05%) ▲|BNY145.32+1.76 (+1.23%) ▲|BRK-B488.49-6.32 (-1.28%) ▼|C145.32+1.73 (+1.20%) ▲|CAT1,044.33+49.88 (+5.02%) ▲|CL91.13-0.75 (-0.82%) ▼|CMCSA22.90+0.26 (+1.15%) ▲|COF203.58+3.10 (+1.55%) ▲|COP106.66-0.26 (-0.24%) ▼|COST948.42-12.55 (-1.31%) ▼|CRM150.00-2.76 (-1.81%) ▼|CSCO118.91-0.83 (-0.69%) ▼|CVS104.47+2.60 (+2.55%) ▲|CVX172.49+1.04 (+0.60%) ▲|DE622.68+21.93 (+3.65%) ▲|DHR194.40+5.53 (+2.93%) ▲|DIS98.63-2.50 (-2.47%) ▼|DUK127.45+0.92 (+0.73%) ▲|EMR143.48+2.04 (+1.44%) ▲|FDX325.11+8.28 (+2.61%) ▲|GD344.82+0.50 (+0.15%) ▲|GE370.58+4.70 (+1.28%) ▲|GEV1,084.85+27.20 (+2.57%) ▲|GILD124.26-0.89 (-0.71%) ▼|GM78.51-0.44 (-0.56%) ▼|GOOG339.93-5.10 (-1.48%) ▼|GOOGL342.25-3.03 (-0.88%) ▼|GS1,069.25-7.66 (-0.71%) ▼|HD342.30-0.56 (-0.16%) ▼|HON230.85+3.43 (+1.51%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC130.00-1.91 (-1.45%) ▼|INTU255.66-6.67 (-2.54%) ▼|ISRG400.58-1.25 (-0.31%) ▼|JNJ245.87+4.87 (+2.02%) ▲|JPM335.97+2.52 (+0.76%) ▲|KO80.39-0.22 (-0.27%) ▼|LIN523.82+8.09 (+1.57%) ▲|LLY1,133.57+16.31 (+1.46%) ▲|LMT505.41+13.77 (+2.80%) ▲|LOW220.47-0.99 (-0.44%) ▼|LRCX393.43+18.61 (+4.97%) ▲|MA493.67-0.74 (-0.15%) ▼|MCD266.69-7.19 (-2.63%) ▼|MDLZ61.64-0.11 (-0.17%) ▼|MDT80.81+0.68 (+0.85%) ▲|META546.15-11.65 (-2.09%) ▼|MMM167.12+1.21 (+0.73%) ▲|MO73.35+1.28 (+1.77%) ▲|MRK125.59+4.99 (+4.13%) ▲|MS221.28+1.42 (+0.65%) ▲|MSFT354.78-10.67 (-2.92%) ▼|MU1,221.22+173.30 (+16.54%) ▲|NEE87.87+0.25 (+0.28%) ▲|NFLX72.05+0.20 (+0.28%) ▲|NKE40.48-1.35 (-3.22%) ▼|NOW90.27-3.53 (-3.76%) ▼|NVDA194.52-4.39 (-2.21%) ▼|ORCL152.56-4.98 (-3.16%) ▼|PEP139.88-2.39 (-1.68%) ▼|PFE23.81-0.24 (-0.98%) ▼|PG148.34-3.70 (-2.43%) ▼|PLTR107.72-5.79 (-5.10%) ▼|PM179.26+1.95 (+1.10%) ▲|QCOM207.57+10.25 (+5.19%) ▲|RTX186.15+1.09 (+0.59%) ▲|SBUX103.37-0.16 (-0.15%) ▼|SCHW89.51-1.88 (-2.06%) ▼|SO95.95+0.17 (+0.18%) ▲|SPG225.65+3.50 (+1.58%) ▲|T22.55+0.18 (+0.81%) ▲|TMO505.68+13.48 (+2.74%) ▲|TMUS182.60+1.81 (+1.00%) ▲|TSLA373.28-2.19 (-0.58%) ▼|TXN310.99+7.88 (+2.60%) ▲|UBER72.67-1.18 (-1.60%) ▼|UNH414.93+9.13 (+2.25%) ▲|UNP266.84+6.88 (+2.64%) ▲|UPS108.52+2.38 (+2.24%) ▲|USB61.03+0.92 (+1.53%) ▲|V334.59+2.36 (+0.71%) ▲|VZ46.13+0.45 (+0.97%) ▲|WFC84.89+0.59 (+0.70%) ▲|WMT116.30-2.71 (-2.28%) ▼|XOM137.52+0.62 (+0.45%) ▲|
28.3 C
New York
Thursday, June 25, 2026

Tag: cancer

newssourceFORcompanyinformationcontent1marketreleases

Block O’Toole & Murphy Raises Over $1,375,000 for St. Jude’s Hospital at Annual New York City Wine Tasting Event

NEW YORK, July 2, 2025 /PRNewswire/ -- New York personal injury law firm Block O'Toole & Murphy is honored to share that the firm raised...

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Cyclists of All Ages and Abilities to Unite for Blood Cancer Patients Along Picturesque Lake Michigan Shoreline

The Leukemia & Lymphoma Society's Scenic Shore Bike Tour Offers a Unique Ride Experience to Help Advance Lifesaving Research, Support, and Advocacy WASHINGTON, July 2,...

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inner Circle acknowledges, Shiva Pejman-Aryan, APRN. FNP-C. PMHNP-BC as a Pinnacle Lifetime Member

AUSTIN, Texas, July 1, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Shiva Pejman-Aryan, APRN. FNP-C. PMHNP-BC and DNP (Candidate) is acknowledged as...

Florida Cancer Specialists & Research Institute Announces Addition Of Specialized Gynecologic Oncology Services in Tampa Bay Communities

Heather Miller, MD Joins Statewide Practice FORT MYERS, Fla., July 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) ) is pleased...

Introducing Aisle10.org: A monthly subscription self-care service for SNAP-eligible Oregonians

PORTLAND, Ore., July 1, 2025 /PRNewswire/ -- In an effort to support good health of Supplemental Nutrition Assistance Program (SNAP) beneficiaries, we are pleased...

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

OneOncology and Pacific Cancer Care Expand Central Coast Cancer Services with Acquisition of Los Gatos Radiation Oncology Center

NASHVILLE, Tenn. and MONTEREY, Calif., July 1, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform supporting independent oncology practices, and its Monterey-based partner Pacific Cancer...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers